SciBase resolves on a directed issued of approximately SEK 33 million and a rights issue of approximately SEK 15 million

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase resolves on a directed issued of approximately SEK 33 million and a rights issue of approximately SEK 15 million weiterlesen

SciBase Partners with Skinobs to Offer Nevisense on Global Cosmetic Testing Platform

Through the Skinobs platform, researchers can easily find information on who is conducting what tests in the field of dermocosmetic, nutraceutical, and active ingredient testing. This collaboration will streamline the process for researchers looking to access the latest tools for their cosmetic and medical research. The cosmetic testing market segment represents a significant potential addressable… SciBase Partners with Skinobs to Offer Nevisense on Global Cosmetic Testing Platform weiterlesen

Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami

At the conference, SciBase presented its product Nevisense – an AI-powered detection enhancement technology that improves the ability for early detection of melanoma at point of care. Melanomas have a fast growth rate and a delay in treatment may mean the difference between life and death. Early detection is the key to survival as melanoma… Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami weiterlesen

New study shows Nevisense evaluates skin barrier function with less sensitivity to lifestyle factors than TEWL

Skin barrier function has been implicated as a driving factor in many dermatological disorders, including Atopic Dermatitis (AD). AD is one of the most prevalent disorders in the world, affecting up to 20% of children globally. Additionally, skin barrier function is commonly assessed in the research and development of pharmaceutics and cosmetic products. The study… New study shows Nevisense evaluates skin barrier function with less sensitivity to lifestyle factors than TEWL weiterlesen

SciBase initiates collaboration with Inderes for commissioned research

The research reports, analyst comments and interview videos will be published and made available on inderes.se, inderes.dk and inderes.fi with over 70,000 active members, as well as through Inderes‘ channels on social media and other investor platforms. The first analysis is planned to be carried out in the first quarter of 2024. Inderes welcomes all… SciBase initiates collaboration with Inderes for commissioned research weiterlesen

Reminder: Welcome to SciBase Capital Markets Day 2024

SciBase has evolved from being an innovation company originating from the Karolinska Institute to a global company dedicated to supporting healthcare professionals in their work by facilitating early detection and prevention of skin cancer and other dermatological conditions. During SciBase’s Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will… Reminder: Welcome to SciBase Capital Markets Day 2024 weiterlesen

Welcome to SciBase Capital Markets Day 2024

SciBase has evolved from being an innovation company originating from the Karolinska Institute to a global company dedicated to supporting healthcare professionals in their work by facilitating early detection and prevention of skin cancer and other dermatological conditions. During SciBase’s Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will… Welcome to SciBase Capital Markets Day 2024 weiterlesen

SciBase capital markets day 2024 – save the date

SciBase has gone from being an innovation Company originating from the Karolinska Institute to a global company that supports physicians in their work by enabling early detection and prevention in skin cancer and other skin diseases. During SciBase’s capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase’s way forward, updated strategy and… SciBase capital markets day 2024 – save the date weiterlesen

Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection

„Through our new partnership with Nevisense, we are now one of the first groups in the country to adopt AI technology that will help our clinicians improve patient outcomes,“ said Dr. Simon Madorsky, medical director and founder of the Skin Cancer and Reconstructive Surgery Center. Dr. Madorsky is also the CME Chair of the SCARS… Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection weiterlesen

SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

„We are excited to integrate the Nevisense test during routine skin exams in several of our California offices and offer our patients the latest AI-driven technology for the earliest possible detection of melanoma.  Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate.  Early testing and… SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California weiterlesen

Besucheradresse